Abstract:Anti-tumour necrosis factor-α (TNF-α) therapy brought new hopes for treating rheumatic diseases but also increased the risk of infection, including mycobacterium tuberculosis (MTb). Conventional screening tools, such as tuberculin skin test (TST), lack sensitivity or specificity. Recently, T-SPOT.TB has been introduced to detect tuberculosis infection. Reports have proved its superior performance in detecting tuberculosis infection in various patient populations than the TST. To compare the value of a T-cell-based enzyme-linked immunospot assay (ELISPOT) T-SPOT.TB and conventional (TST) in screening and monitoring tuberculosis in patients with rheumatic diseases during infliximab therapy in China. Fifty-eight patients with various rheumatic diseases who received infliximab therapy were enrolled in the trial. Freshly isolated peripheral blood mononuclear cells were stimulated with MTb-specific antigens (ESAT-6 and CFP10), and IFN-γ-producing cells were counted. TST was performed with 1 TU PPD injected intradermally into the volar aspect of forearm. A cutaneous induration with diameter ≥5 mm was considered as positive TST, and an increment ≥5 mm of cutaneous induration was considered as TST conversion. TST and T-SPOT.TB test were carried out at baseline and repeated 12 months after infliximab therapy (if no active TB occurs) or at times when TB occurred. Moreover, all patients were initially evaluated for latent tuberculosis infection (LTBI) with clinical examination and chest radiograph. The McNemar test was used for TST and T-SPOT.TB concordance analysis. Cohen’s kappa coefficient was used to assess strength of the agreement. Among the 58 patients evaluated, 25 (43.1%) had ankylosing spondylitis, 24 (41.4%) had rheumatoid arthritis, 4 (6.9%) had undifferentiated spondyloarthropathy, 3 (5.2%) had psoriatic arthritis and 2 (3.4%) had reactive arthritis. A total of 52 patients (89.7%) had previously received vaccination with Bacille Calmette-Guerin. All of the patients received either single or combination of disease modifying anti-rheumatic drug (DMARDs) therapy, and 16 (27.4%) had previously or presently received glucocorticoid therapy. Before infliximab therapy, 12 patients (20.7%) had positive and 46 (79.3%) had negative TST results, and only 1 (1.7%) had positive T-SPOT.TB. Among 51 patients completing the repeated TST and T-SPOT.TB assay, 7 patients (13.7%) had TST conversion and 4 (7.8%) had positive T-SPOT.TB results. Of 7 patients with TST conversion, 2 patients (28.6%) developed active TB and also had positive T-SPOT.TB results; of 44 patients with no TST conversion, 2 patients (4.5%) had positive T-SPOT.TB and 1 (2.3%) had active TB. If 5 mm was used as the cut-off value of TST, TST and T-SPOT.TB, had an agreement value of 68.6% with a kappa value of 0.166. If 10 mm was used as the cut-off value, the agreement between TST and T-SPOT.TB was 88.2% with a kappa value of 0.338. T-SPOT.TB was more specific than TST in detecting tuberculosis during infliximab therapy in China with high BCG vaccination and high prevalence of TB. It can be used as a reliable tool for TB monitoring during infliximab therapy in Chinese patients with rheumatic diseases. Finally, it is recommended to repeat the TST and T-SPOT.TB periodically during biological treatment.

Risk of Tuberculosis During Infliximab Therapy for Inflammatory Bowel Disease, Rheumatoid Arthritis, and Spondyloarthropathy: A Meta-Analysis

P-030 Infliximab and Tuberculosis Infection

P568 Does Infliximab Therapy Increase Incidence of Tuberculosis in Patients with Inflammatory Bowel Disease in an Endemic Area: a Nationwide Study from China

P482 Selective Prophylactic Anti-Tuberculosis Strategy is Superior for Chinese Patients with Inflammatory Bowel Disease Receiving Infliximab Treatment: a Multi-Centre Retrospective Study

Risk Of Tuberculosis In Patients Treated With Tnf-Alpha Antagonists: A Systematic Review And Meta-Analysis Of Randomised Controlled Trials

Investigation on status quo of tuberculosis screening in 1711 patients with inflammatory bowel diseases before infliximab therapy in China

Analysis of Adverse Effects of Infliximab Treatment in 486 Patients with Crohn′s Disease

Risk of Infection in Patients with Spondyloarthritis and Ankylosing Spondylitis Receiving Antitumor Necrosis Factor Therapy: A Meta-Analysis of Randomized Controlled Trials.

P502 Different Presentation of Tuberculosis Associated with Anti-Tnf Therapy among Patients with Inflammatory Bowel Disease in Endemic Area: Observation from China

IDDF2018-ABS-0061 Risk of Tuberculosis in Inflammatory Bowel Disease and Other Immune-Mediated Diseases on Biological Therapy: a Population-Based Study in Hong Kong

Risk of Tuberculosis in Patients with Immune-Mediated Diseases on Biological Therapies: a Population-Based Study in a Tuberculosis Endemic Region

Meta analysis of infection risks of anti-TNF-α treatment in rheumatoid arthritis]

The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-Alpha Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies

The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies.

Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region

A T-cell-based enzyme-linked immunospot assay for tuberculosis screening in Chinese patients with rheumatic diseases receiving infliximab therapy

Risk of tuberculosis with anti-TNF therapy in Indian patients with inflammatory bowel disease despite negative screening

P652 Compare Risk Factors Associated with Infectious Complication in Crohn’s Disease with and Without Preoperative Infliximab

Anti‐TNF and Immunosuppressive Combination Therapy is Preferential to Inducing Clinical Remission in Patients with Active Inflammatory Bowel Disease: A Systemic Review and Meta‐analysis

TNF-α inhibitors can increase the risk of respiratory infection when used in rheumatism: a meta-analysis and systematic review

Effectiveness and risk associated with infliximab alone and in combination with immunosuppressors for Crohn’s disease: a systematic review and meta-analysis